Bayer-Onyx DECISION trial of Nexavar meets primary endpoint

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that the stuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine refractory thyrOid caNcer (DECIS…

---

Alkermes plc Expands CNS Pipeline and Announces Positive Results From Phase 1 Study of ALKS 3831, a Novel Antipsychotic Therapy for the Treatment of Schizophrenia

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced positive topline results from a phase 1 study of its new antipsychotic candidate, ALKS 3831, a combination of a proprietary drug mo…

---

Merck Announces HPS2THRIVE Study of TREDAPTIVE ExtendedRelease NiacinLaropiprant Did Not Achieve Primary Endpoint

Merck NYSEMRK known outside the United States and Canada as MSD today announced that the HPS2THRIVE Heart Protection Study 2Treatment of HDL to Reduce the Incidence of Vascular Event…

---

Innate Pharma: Phase I Clinical Trial of IPH2102/BMS-986015 in Combination With Ipilimumab Announced

A Phase I Study of the Anti-KIR Antibody IPH2102/BMS-986015 in Combination With Ipilimumab in Patients With Selected Advanced Solid Tumors Published on ClinicalTrials.gov…

---